AIM Immunotech Inc. Enters Agreement with Thermo Fisher for Phase 3 Trial of Ampligen
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: moomoo
Agreement Announcement: AIM Immunotech has signed an agreement with the Thermo Fisher Scientific for the Phase 3 trial of its drug Ampligen.
Trial Focus: The Phase 3 trial will focus on evaluating the efficacy and safety of Ampligen in treating specific medical conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AIM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AIM
Wall Street analysts forecast AIM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.772
Low
22.00
Averages
22.00
High
22.00
Current: 0.772
Low
22.00
Averages
22.00
High
22.00
No data
About AIM
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AIM Immunotech Inc. Enters Agreement with Thermo Fisher for Phase 3 Trial of Ampligen
Agreement Announcement: AIM Immunotech has signed an agreement with the Thermo Fisher Scientific for the Phase 3 trial of its drug Ampligen.
Trial Focus: The Phase 3 trial will focus on evaluating the efficacy and safety of Ampligen in treating specific medical conditions.
See More
AIM ImmunoTech Announces Rights Offering Details
- Rights Offering Initiation: AIM ImmunoTech has announced that its rights offering commenced on February 11, 2026, and is expected to expire on February 27, 2026; if fully subscribed, it anticipates raising $12 million, enhancing liquidity to support Ampligen® development.
- Subscription Rights Details: Each shareholder will receive one subscription right allowing them to purchase up to 12,000 units at $1,000 per unit, with each unit comprising one share of convertible preferred stock and 1,666 warrants, thereby increasing shareholder engagement and optimizing capital structure.
- Conversion and Exercise Terms: Each share of preferred stock can be converted into 833 shares of common stock at a conversion price of $1.20 per share, with warrants exercisable for five years post-issuance, ensuring shareholders have opportunities to increase their stake and strengthen the shareholder base.
- Regulatory Compliance: The rights offering is conducted in accordance with SEC registration statements, ensuring transparency and compliance, while shareholders must independently assess whether to exercise their rights, reflecting the company's commitment to shareholder interests.
See More
AIM ImmunoTech Launches Rights Offering for $12 Million
- Rights Offering Initiation: AIM ImmunoTech has launched a rights offering aiming to raise $12 million, demonstrating the company's commitment to addressing the global health challenge of late-stage pancreatic cancer treatment.
- Subscription Rights Allocation: Each shareholder will receive subscription rights based on their common stock holdings, allowing them to purchase up to 12,000 units at $1,000 per unit, enhancing shareholder engagement and liquidity.
- Oversubscription Privilege: Shareholders who fully exercise their basic subscription rights can subscribe for additional units, with remaining units allocated pro-rata among over-subscribers, ensuring fairness and incentivizing active participation.
- Defined Offering Period: The subscription rights are exercisable from February 11 to February 27, 2026, with unexercised rights expiring, emphasizing the importance of timely decision-making for shareholders in their investment strategies.
See More
AIM ImmunoTech to Participate in Corporate Connect Webinar
- Webinar Participation: AIM ImmunoTech will participate in the Corporate Connect Webinar hosted by Webull Financial on February 11, 2026, at 1:40 PM EST, where CEO Thomas K. Equels will provide a corporate overview and business outlook, emphasizing the company's strategic focus on pancreatic cancer.
- Strategic Focus: The presentation will highlight AIM's strategic emphasis on pancreatic cancer treatment, showcasing the latest advancements in its immunotherapy research, aimed at boosting investor confidence in the company's future potential.
- Product Introduction: AIM's lead product, Ampligen®, is a first-in-class investigational drug acting as a TLR3 agonist, currently undergoing clinical trials for various cancers and viral diseases, demonstrating broad therapeutic potential.
- Investor Relations: Through this webinar, AIM ImmunoTech aims to engage with investors, showcasing its innovative capabilities in cancer treatment and seeking to attract more investor attention towards its R&D progress and market outlook.
See More
U.S. Stocks Decline in Morning Trading
- Market Performance: U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 200 points and the S&P 500 down 0.74% to 6,831.80, indicating weakened market sentiment and heightened investor concerns about future economic prospects.
- Sector Dynamics: Consumer staples stocks gained 0.3%, while consumer discretionary stocks fell by 2.2%, reflecting a divergence in market confidence across different consumer sectors, which could impact short-term performance of related companies.
- Economic Data: U.S. job openings declined by 386,000 to 6.542 million in December, significantly below market estimates of 7.2 million, indicating a tightening labor market that may affect future economic growth expectations.
- Initial Jobless Claims: Initial jobless claims rose by 22,000 to 231,000, exceeding market expectations of 212,000, suggesting potential pressures on the labor market that could further impact consumer confidence and spending.
See More
Healthcare Stocks Show Weak Momentum and High Valuation
- Weak Momentum Ratings: According to the SA grading system, AIM ImmunoTech (AIM), AirSculpt Technologies (AIRS), and Applied Therapeutics (APLT) all received an 'F' momentum grade, indicating extremely poor price performance that may lead to declining investor confidence.
- High Valuation Ratings: AirSculpt Technologies (AIRS) holds a Quant Rating of 1.03, designated as a Strong Sell, reflecting its overvaluation relative to fundamentals, which could adversely affect its future market performance.
- Overall Poor Market Performance: The majority of the listed healthcare stocks fall within Hold or Strong Sell ratings, indicating that the sector is facing challenges in price performance, prompting investors to carefully assess risks.
- Momentum and Valuation Relationship: Momentum grades range from A+ to F, with F representing the lowest momentum, highlighting the vulnerability of these healthcare stocks in the current market environment, which may influence investor decision-making.
See More
AIM Immunotech Inc. Enters Agreement with Thermo Fisher for Phase 3 Trial of Ampligen
Agreement Announcement: AIM Immunotech has signed an agreement with the Thermo Fisher Scientific for the Phase 3 trial of its drug Ampligen.
Trial Focus: The Phase 3 trial will focus on evaluating the efficacy and safety of Ampligen in treating specific medical conditions.
See More
AIM ImmunoTech Announces Rights Offering Details
- Rights Offering Initiation: AIM ImmunoTech has announced that its rights offering commenced on February 11, 2026, and is expected to expire on February 27, 2026; if fully subscribed, it anticipates raising $12 million, enhancing liquidity to support Ampligen® development.
- Subscription Rights Details: Each shareholder will receive one subscription right allowing them to purchase up to 12,000 units at $1,000 per unit, with each unit comprising one share of convertible preferred stock and 1,666 warrants, thereby increasing shareholder engagement and optimizing capital structure.
- Conversion and Exercise Terms: Each share of preferred stock can be converted into 833 shares of common stock at a conversion price of $1.20 per share, with warrants exercisable for five years post-issuance, ensuring shareholders have opportunities to increase their stake and strengthen the shareholder base.
- Regulatory Compliance: The rights offering is conducted in accordance with SEC registration statements, ensuring transparency and compliance, while shareholders must independently assess whether to exercise their rights, reflecting the company's commitment to shareholder interests.
See More
AIM ImmunoTech Launches Rights Offering for $12 Million
- Rights Offering Initiation: AIM ImmunoTech has launched a rights offering aiming to raise $12 million, demonstrating the company's commitment to addressing the global health challenge of late-stage pancreatic cancer treatment.
- Subscription Rights Allocation: Each shareholder will receive subscription rights based on their common stock holdings, allowing them to purchase up to 12,000 units at $1,000 per unit, enhancing shareholder engagement and liquidity.
- Oversubscription Privilege: Shareholders who fully exercise their basic subscription rights can subscribe for additional units, with remaining units allocated pro-rata among over-subscribers, ensuring fairness and incentivizing active participation.
- Defined Offering Period: The subscription rights are exercisable from February 11 to February 27, 2026, with unexercised rights expiring, emphasizing the importance of timely decision-making for shareholders in their investment strategies.
See More
AIM ImmunoTech to Participate in Corporate Connect Webinar
- Webinar Participation: AIM ImmunoTech will participate in the Corporate Connect Webinar hosted by Webull Financial on February 11, 2026, at 1:40 PM EST, where CEO Thomas K. Equels will provide a corporate overview and business outlook, emphasizing the company's strategic focus on pancreatic cancer.
- Strategic Focus: The presentation will highlight AIM's strategic emphasis on pancreatic cancer treatment, showcasing the latest advancements in its immunotherapy research, aimed at boosting investor confidence in the company's future potential.
- Product Introduction: AIM's lead product, Ampligen®, is a first-in-class investigational drug acting as a TLR3 agonist, currently undergoing clinical trials for various cancers and viral diseases, demonstrating broad therapeutic potential.
- Investor Relations: Through this webinar, AIM ImmunoTech aims to engage with investors, showcasing its innovative capabilities in cancer treatment and seeking to attract more investor attention towards its R&D progress and market outlook.
See More
U.S. Stocks Decline in Morning Trading
- Market Performance: U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 200 points and the S&P 500 down 0.74% to 6,831.80, indicating weakened market sentiment and heightened investor concerns about future economic prospects.
- Sector Dynamics: Consumer staples stocks gained 0.3%, while consumer discretionary stocks fell by 2.2%, reflecting a divergence in market confidence across different consumer sectors, which could impact short-term performance of related companies.
- Economic Data: U.S. job openings declined by 386,000 to 6.542 million in December, significantly below market estimates of 7.2 million, indicating a tightening labor market that may affect future economic growth expectations.
- Initial Jobless Claims: Initial jobless claims rose by 22,000 to 231,000, exceeding market expectations of 212,000, suggesting potential pressures on the labor market that could further impact consumer confidence and spending.
See More
Healthcare Stocks Show Weak Momentum and High Valuation
- Weak Momentum Ratings: According to the SA grading system, AIM ImmunoTech (AIM), AirSculpt Technologies (AIRS), and Applied Therapeutics (APLT) all received an 'F' momentum grade, indicating extremely poor price performance that may lead to declining investor confidence.
- High Valuation Ratings: AirSculpt Technologies (AIRS) holds a Quant Rating of 1.03, designated as a Strong Sell, reflecting its overvaluation relative to fundamentals, which could adversely affect its future market performance.
- Overall Poor Market Performance: The majority of the listed healthcare stocks fall within Hold or Strong Sell ratings, indicating that the sector is facing challenges in price performance, prompting investors to carefully assess risks.
- Momentum and Valuation Relationship: Momentum grades range from A+ to F, with F representing the lowest momentum, highlighting the vulnerability of these healthcare stocks in the current market environment, which may influence investor decision-making.
See More
